Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2017 1
2018 1
2020 1
2021 1
2022 3
2023 3
2024 4
2025 3
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Clinical value of preoperative serum tumor markers CEA, CA19-9, CA125, and CA15-3 in surgically treated urachal cancer.
Stokkel LE, van Rossum HH, van de Kamp MW, Boellaard TN, Bekers EM, Kok NFM, van Rhijn BWG, Mertens LS. Stokkel LE, et al. Among authors: van de kamp mw. Urol Oncol. 2023 Jul;41(7):326.e17-326.e24. doi: 10.1016/j.urolonc.2023.01.018. Epub 2023 Feb 21. Urol Oncol. 2023. PMID: 36813613
The aim of this study was to assess the clinical value of elevated STMs including carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), cancer antigen 125 (CA125), and cancer antigen 15-3 (CA15-3) in surgically treated UrAC, and to evaluate their prog …
The aim of this study was to assess the clinical value of elevated STMs including carcinoembryonic antigen (CEA), cancer antigen 19-9 …
Does a better adherence to dietary guidelines reduce mortality risk and environmental impact in the Dutch sub-cohort of the European Prospective Investigation into Cancer and Nutrition?
Biesbroek S, Verschuren WMM, Boer JMA, van de Kamp ME, van der Schouw YT, Geelen A, Looman M, Temme EHM. Biesbroek S, et al. Among authors: van de kamp me. Br J Nutr. 2017 Jul;118(1):69-80. doi: 10.1017/S0007114517001878. Epub 2017 Aug 3. Br J Nutr. 2017. PMID: 28768562 Free PMC article.
In the Dutch sub-cohort of the European Prospective Investigation into Cancer and Nutrition, the diet was assessed with a 178-item FFQ of 40 011 participants aged 20-70 years between 1993 and 1997. ...
In the Dutch sub-cohort of the European Prospective Investigation into Cancer and Nutrition, the diet was assessed with a 178-item FF …
High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.
van Dorp J, Pipinikas C, Suelmann BBM, Mehra N, van Dijk N, Marsico G, van Montfoort ML, Hackinger S, Braaf LM, Amarante T, van Steenis C, McLay K, Daletzakis A, van den Broek D, van de Kamp MW, Hendricksen K, de Feijter JM, Boellaard TN, Meijer RP, van der Heijden AG, Rosenfeld N, van Rhijn BWG, Jones G, van der Heijden MS. van Dorp J, et al. Among authors: van de kamp mw. Nat Med. 2023 Mar;29(3):588-592. doi: 10.1038/s41591-022-02199-y. Epub 2023 Feb 2. Nat Med. 2023. PMID: 36732628 Clinical Trial.
Cohort 1 of the phase 1B NABUCCO trial showed high pathological complete response (pCR) rates with preoperative ipilimumab plus nivolumab in stage III urothelial cancer (UC). In cohort 2, the aim was dose adjustment to optimize responses. Additionally, we report secondary …
Cohort 1 of the phase 1B NABUCCO trial showed high pathological complete response (pCR) rates with preoperative ipilimumab plus nivolumab in …
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy.
Claps F, van de Kamp MW, Mayr R, Bostrom PJ, Shariat SF, Hippe K, Bertz S, Neuzillet Y, Sanders J, Otto W, van der Heijden MS, Jewett MAS, Stöhr R, Zlotta AR, Trombetta C, Eckstein M, Mertens LS, Burger M, Soorojebally Y, Wullich B, Bartoletti R, Radvanyi F, Pavan N, Sirab N, Mir MC, Pouessel D, van der Kwast TH, Hartmann A, Lotan Y, Bussani R, Allory Y, van Rhijn BWG. Claps F, et al. Among authors: van de kamp mw. BJU Int. 2023 Aug;132(2):170-180. doi: 10.1111/bju.15984. Epub 2023 Feb 20. BJU Int. 2023. PMID: 36748180 Free article.
OBJECTIVES: To evaluate variant histologies (VHs) for disease-specific survival (DSS) in patients with invasive urothelial bladder cancer (BCa) undergoing radical cystectomy (RC). MATERIALS AND METHODS: We analysed a multi-institutional cohort of 1082 patients treated with …
OBJECTIVES: To evaluate variant histologies (VHs) for disease-specific survival (DSS) in patients with invasive urothelial bladder cancer …
Robot-Assisted Partial Cystectomy versus Open Partial Cystectomy for Patients with Urachal Cancer.
Stokkel LE, van de Kamp MW, Schaake EE, Boellaard TN, Hendricksen K, van Rhijn BWG, Mertens LS. Stokkel LE, et al. Among authors: van de kamp mw. Urol Int. 2022;106(8):840-847. doi: 10.1159/000521605. Epub 2022 Feb 8. Urol Int. 2022. PMID: 35134799
INTRODUCTION: Localized urachal cancer (UrC) can be treated with an open partial cystectomy (OPC) with en bloc resection of the urachal remnant and umbilicus. ...
INTRODUCTION: Localized urachal cancer (UrC) can be treated with an open partial cystectomy (OPC) with en bloc resection of the urach …
Long-term quality of life in patients with bladder cancer following radical cystectomy.
Akdemir E, Stuiver MM, van de Kamp MW, der Hulst JB, Mertens LS, Hendricksen K, van Harten WH, May AM, Sweegers MG. Akdemir E, et al. Among authors: van de kamp mw. BJU Int. 2025 Apr;135(4):675-683. doi: 10.1111/bju.16610. Epub 2024 Dec 1. BJU Int. 2025. PMID: 39617009 Free PMC article.
PATIENTS AND METHODS: Patients with bladder cancer were invited to complete QoL questionnaires at 3-month intervals in the first year and yearly thereafter. ...
PATIENTS AND METHODS: Patients with bladder cancer were invited to complete QoL questionnaires at 3-month intervals in the first year …
Renal cancer seeding metastases following retroperitoneoscopic-assisted cryoablation: A case report.
van de Kamp MW, Kortekaas B, Lagerveld BW. van de Kamp MW, et al. Can Urol Assoc J. 2015 Sep-Oct;9(9-10):E641-3. doi: 10.5489/cuaj.2850. Epub 2015 Sep 9. Can Urol Assoc J. 2015. PMID: 26425230 Free PMC article.
The combination of two events as harming the integrity of cancer tissue and gas-circulation leading to the development of metastases in the retroperitoneal cavity is discussed. The combination of iatrogenic harming cancer tissue integrity and CO2-circulation leads t …
The combination of two events as harming the integrity of cancer tissue and gas-circulation leading to the development of metastases …
Survival after neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer.
Einerhand SMH, van Dijk N, van Dorp J, de Feijter JM, van Montfoort ML, van de Kamp MW, Schaake EE, Boellaard TN, Hendricksen K, van der Heijden MS, van Rhijn BWG. Einerhand SMH, et al. Among authors: van de kamp mw. Int J Cancer. 2022 Dec 1;151(11):2004-2011. doi: 10.1002/ijc.34125. Epub 2022 Jun 10. Int J Cancer. 2022. PMID: 35603905 Clinical Trial.
We identified 602 patients who attended our outpatient bladder cancer clinic in 2018 to 2019. Patients were included if they received NAIC or cICI for cT3-4aN0M0 or cT1-4aN1-3M0 UC. ...
We identified 602 patients who attended our outpatient bladder cancer clinic in 2018 to 2019. Patients were included if they received …
A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice.
de Ruiter BM, van de Kamp MW, van Steenbergen JPZ, Franckena M, Boormans JL, de Feijter JM, Bins AD, Hulshof MCCM, de Reijke TM, Schaake E, Oddens JR. de Ruiter BM, et al. Among authors: van de kamp mw. Eur Urol Open Sci. 2022 Mar 16;39:7-13. doi: 10.1016/j.euros.2022.02.010. eCollection 2022 May. Eur Urol Open Sci. 2022. PMID: 35528785 Free PMC article.
Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil.
Voskuilen CS, van de Kamp MW, Schuring N, Mertens LS, Noordzij A, Pos F, van Rhijn BWG, van der Heijden MS, Schaake EE. Voskuilen CS, et al. Among authors: van de kamp mw. Radiother Oncol. 2020 Sep;150:275-280. doi: 10.1016/j.radonc.2020.07.057. Epub 2020 Aug 6. Radiother Oncol. 2020. PMID: 32768507
BACKGROUND AND PURPOSE: Chemoradiation (CRT) with mitomycin-C (MMC) and 5-fluorouracil (5-FU) has been shown to be superior to radiation alone in patients with muscle-invasive bladder cancer (MIBC). MMC/capecitabine is an effective replacement for 5FU as a radiosensitizer …
BACKGROUND AND PURPOSE: Chemoradiation (CRT) with mitomycin-C (MMC) and 5-fluorouracil (5-FU) has been shown to be superior to radiation alo …
16 results